Skip to main content
Kane Biotech Inc. logo

Kane Biotech Inc. — Investor Relations & Filings

Ticker · KNE ISIN · CA4838092084 TSXV Manufacturing
Open in API
Filings indexed 218 across all filing types
Latest filing 2026-04-24 Earnings Release
Country CA Canada
Listing TSXV KNE

About Kane Biotech Inc.

https://kanebiotech.com/

Kane Biotech Inc. is a biotechnology company engaged in the research, development, and commercialization of proprietary technologies designed to prevent and remove microbial biofilms, which are a major contributor to chronic infections and impaired healing. The company holds extensive intellectual property related to biofilm formation and dispersal mechanisms, utilizing proprietary technologies such as DispersinB® and coactiv+®. Its primary commercial focus is advanced wound care, where products like the revyve® Antimicrobial Wound Gel and Spray are designed to disrupt biofilms and promote healing. The product pipeline also includes surgical and dermatological applications for both human and animal health.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Earnings Release Classification · 1% confidence The document is a press release announcing fourth quarter and full year 2025 financial results with selected metrics and highlights. It provides revenue, profit/loss figures, corporate updates, and forward-looking statements, but is not the full Annual Report or MD&A. This matches the definition of an "Earnings Release" (initial announcement of quarterly/periodical financial results). FY 2025
2026-04-24 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing the presentation of clinical data at a scientific conference (Symposium on Advanced Wound Care). It does not present financial results (not an Earnings Release), is not a regulatory form or report itself (e.g., 10-K, IR, AR), nor is it a shareholder meeting or capital change announcement. It is a general corporate news release that does not fit any other specific category, making it a fallback “Regulatory Filings” (RNS) item.
2026-04-16 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 1% confidence The document is a transfer agent notice from TSX Trust Company confirming the record and meeting dates for an upcoming annual and special meeting of security holders. It contains no financial results, proxy materials or vote outcomes, and is not the proxy statement itself but rather a regulatory notice. This does not fit into specific categories like 10-K, ER, DVA, PSI, or others. Thus it is classified as a general regulatory filing (RNS).
2026-04-13 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 1% confidence The document is a TSX Trust Company letter confirming the Notice of Record and Meeting Dates for Kane Biotech’s upcoming Annual and Special Meeting of security holders. It is not the proxy statement itself (no solicitation materials attached), nor is it an AGM presentation or voting results—it merely confirms administrative meeting logistics. This does not match any of the specific filing types (e.g., AGM materials, proxy statement, dividend notice, etc.), so it falls into the general regulatory announcement category.
2026-04-13 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 45-106F1 Report of Exempt Distribution', which is a standard regulatory filing in Canada used to report the distribution of securities under prospectus exemptions. It details the issuer (Kane Biotech Inc.), the distribution date, the number of securities issued, and the exemption relied upon. Since this is a specific regulatory form required by Canadian securities commissions for capital-raising activities, it falls under the 'Regulatory Filings' category as it does not fit into the more specific categories like 'Share Issue' (which usually refers to public offerings or general capital changes) or 'Capital/Financing Update' (which is typically a press release).
2025-12-23 English
Material change report - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a 'Material Change Report' (Form 51-102F3) filed by Kane Biotech Inc. regarding the completion of a private placement offering of common shares. While it includes a press release as an attachment, the primary document is a formal regulatory filing detailing a specific capital-raising event (issuance of 14,000,000 shares). Under the provided categories, this fits best as a 'Share Issue/Capital Change' (SHA) as it describes the issuance of new shares and the resulting change in capital structure.
2025-12-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.